Multiple drug delivery from a balloon and a prosthesis
First Claim
1. A method for treating vascular disease comprising:
- providing a balloon having an outer surface and a coming disposed on at least a portion of the outer surface, the coating including an initial amount of a cytostatic agent selected from the group consisting of zotarolimus, everolimus, pimecrolimus, or a combination thereof, the coating being capable of maintaining a therapeutically effective amount of the cytostatic agent on the outer surface for delivery to a vessel wall;
positioning the balloon at a lesion site along the vessel wail; and
expanding the balloon for temporary contact of the outer surface with the vessel wall to deliver the therapeutically effective amount of the cytostatic agent to the vessel wall at the lesion site, wherein between about 4.9% to about 23% of the initial amount of the cytostatic agent remains disposed on the outer surface after delivery of the therapeutically effective amount of the cytostatic agent to the vessel wall.
0 Assignments
0 Petitions
Accused Products
Abstract
Disclosed is an interventional device for delivery of therapeutic agents from an angioplasty balloon and from a prosthesis such as an intraluminal stent. The invention also relates to the method of loading the beneficial agents onto the balloon and the device, as well as the method of delivery of the agents from separate surfaces. The invention also relates to an interventional device having a prosthesis surface that is loaded with a first beneficial agent, and a balloon surface loaded with a second beneficial agent. The invention also relates to a method of loading multiple beneficial agents onto the prosthesis surfaces and the balloon surfaces, and to a method of manufacturing an interventional device for the delivery of a first beneficial agent and a second beneficial agent from separate surfaces.
135 Citations
14 Claims
-
1. A method for treating vascular disease comprising:
- providing a balloon having an outer surface and a coming disposed on at least a portion of the outer surface, the coating including an initial amount of a cytostatic agent selected from the group consisting of zotarolimus, everolimus, pimecrolimus, or a combination thereof, the coating being capable of maintaining a therapeutically effective amount of the cytostatic agent on the outer surface for delivery to a vessel wall;
positioning the balloon at a lesion site along the vessel wail; and
expanding the balloon for temporary contact of the outer surface with the vessel wall to deliver the therapeutically effective amount of the cytostatic agent to the vessel wall at the lesion site, wherein between about 4.9% to about 23% of the initial amount of the cytostatic agent remains disposed on the outer surface after delivery of the therapeutically effective amount of the cytostatic agent to the vessel wall. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
- providing a balloon having an outer surface and a coming disposed on at least a portion of the outer surface, the coating including an initial amount of a cytostatic agent selected from the group consisting of zotarolimus, everolimus, pimecrolimus, or a combination thereof, the coating being capable of maintaining a therapeutically effective amount of the cytostatic agent on the outer surface for delivery to a vessel wall;
Specification